Effects of sodium glucose co-transporter-2 inhibitor on atrial arrhythmia burden in patient with cardiovascular implantable electronic device: a randomized controlled trial
- Conditions
- Atrial fibrillation in patients with cardiac implantable electronic device
- Registration Number
- TCTR20210315003
- Lead Sponsor
- Faculty of Medicine, Chiang Mai University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 166
1. Presence of dual chamber CIED (pacemaker or defibrillator) for at least 3 months, 2. Age > 18 years old, 3. Atrial high rate episode (AHRE) with atrial rate >170 beats per minute of more than 6 minutes, 4. Given informed consent
1. Currently taking SGLT2i, 2. Permanent AF or long-standing persistent AF, 3. Estimated GFR <25 mL/min/1.73 m2, 4. Pregnant or lactation, 5. SBP <95mmHg or symptoms of hypotension, 6. Hospitalized, ACS, CABG, PCI, or cardioversion within 3 months, 7. Atrial arrhythmia ablation within previous 3 months or currently plan, 8. Bladder cancer, 9. History of genital infection within 3 months, 10. History of frequent urinary tract infection (UTI) (>=2 UTI in 6 months or >=3 UTI in 12 months), 11. DM type 1
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method ongest atrial tachycardia/atrial fibrillation episode baseline, 3 months Minutes
- Secondary Outcome Measures
Name Time Method